Effects of cerivastatin in dyslipemia and other cardiovascular risk factors after renal transplantation.
Garcia
I
I
Renal Unit, University Clinic, University of Navarra, Pamplona, Spain.
Errasti
P
P
Lavilla
F J
FJ
Ballester
B
B
Manrique
J
J
Rossich
E
E
Purroy
A
A
D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D008055:Lipids; D008074:Lipoproteins; D011725:Pyridines; D002784:Cholesterol; C086276:cerivastatin